Sales receipts for the September quarter suggest that the rate of deliveries for Labcon slowedin the Sept quarter. Was this planned and what rate should we expect in the coming quarters?MD: This certainly was planned. Towards the end of the calendar year and especially into calendar2019 there will be a substantial ramp in volumes to meet the FY19 $US1.1m commitment fromLabcon.
Labcon is putting in place the processes for scaled manufacture and progressing registrationof the Bluechiip enabled range. We at Bluechiip are also in the process of registering and scalingthe reader and software range, with both the Multi Vial Reader and Handheld readers movinginto production at Planet Innovation.
As per my past posts, sales in September quarter would be affected due to contract negotiations and rescheduling of volumes and ramp up planning. No surprise there and sales from Labcon only in FY19 to be around A$1.5m ish.. as suggested previously.
- Forums
- ASX - By Stock
- BCT
- Ann: Appendix 4C - quarterly
Ann: Appendix 4C - quarterly, page-3
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.737M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BCT (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online